News Acrivon Therapeutics, Inc.

Equities

ACRV

US0048901096

Market Closed - Nasdaq Other stock markets 01:29:50 31/05/2024 am IST			5-day change	1st Jan Change
7.55 ^USD	+0.67%		-6.91%	+53.46%

14/05	Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
30/04	North American Morning Briefing : More Earnings -2-	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference	29/05	GL
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights	14/05	GL
Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
North American Morning Briefing : More Earnings -2-	30/04	DJ
Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral	29/04	MT
Piper Sandler Adjusts Price Target on Acrivon Therapeutics to $30 From $26, Keeps Overweight Rating	25/04	MT
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event	25/04	GL
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress At Corporate R&D Event	25/04	CI
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316	17/04	GL
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368	10/04	GL
Top Midday Gainers	09/04	MT
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	09/04	MT
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday on Caution Ahead of Inflation Data	09/04	MT
Acrivon Therapeutics Announces Private Placement of 8.2 Million Shares; Shares Surge	09/04	MT
Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell	09/04	MT
Top Premarket Gainers	09/04	MT
Acrivon Therapeutics Announces $130 Million Private Placement Financing	09/04	GL
Ladenburg Thalmann Cuts Price Target on Acrivon Therapeutics to $14 From $18, Maintains Buy Rating	05/04	MT
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	28/03	GL
Acrivon Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Acrivon Therapeutics, Inc.

Equities

ACRV

US0048901096

Summary

Filters